Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
3.600
-0.050 (-1.37%)
Feb 5, 2026, 4:00 PM EST - Market closed
Relmada Therapeutics Analyst Ratings
Total Analysts
3
Consensus Rating
Strong Buy
Price Target
$9.00
Upside
+150.00%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $8 | Hold → Buy | Upgrades | $8 | +122.22% | Jan 23, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +150.00% | Dec 22, 2025 |
| Mizuho | Mizuho | Hold → Buy Upgrades $1 → $10 | Hold → Buy | Upgrades | $1 → $10 | +177.78% | Nov 19, 2025 |
| Mizuho | Mizuho | Buy → Hold Downgrades $23 → $1 | Buy → Hold | Downgrades | $23 → $1 | -72.22% | Dec 5, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $1 | Buy → Hold | Downgrades | $10 → $1 | -72.22% | Dec 4, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +261.11% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | -44.44% | Jun 5, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +622.22% | Jun 15, 2023 |
| SVB Leerink | SVB Leerink | Buy Maintains $42 → $10 | Buy | Maintains | $42 → $10 | +177.78% | Jan 23, 2023 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $8 | Strong Buy → Hold | Downgrades | $8 | +122.22% | Oct 14, 2022 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 14, 2022 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 13, 2022 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $49 → $81 | Strong Buy | Maintains | $49 → $81 | +2,150.00% | Sep 23, 2022 |
| Guggenheim | Guggenheim | Strong Buy Maintains $50 → $60 | Strong Buy | Maintains | $50 → $60 | +1,566.67% | Sep 6, 2022 |
| Oppenheimer | Oppenheimer | Buy Maintains $75 → $64 | Buy | Maintains | $75 → $64 | +1,677.78% | May 9, 2022 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $69 → $53 | Strong Buy | Maintains | $69 → $53 | +1,372.22% | Mar 24, 2022 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.